RT Journal Article
SR Electronic
T1 An immune-protein signature combining TRAIL, IP-10 and CRP for accurate prediction of severe COVID-19 outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.27.21259196
DO 10.1101/2021.06.27.21259196
A1 Mastboim, Niv Samuel
A1 Angel, Alon
A1 Shaham, Oded
A1 Ber, Tahel Ilan
A1 Navon, Roy
A1 Simon, Einav
A1 Rosenberg, Michal
A1 Israeli, Yael
A1 Hainrichson, Mary
A1 Avni, Noa
A1 Reiner, Eran
A1 Feigin, Paul
A1 Oved, Kfir
A1 Tadmor, Boaz
A1 Singer, Pierre
A1 Kagan, Ilya
A1 Lev, Shaul
A1 Diker, Dror
A1 Jarjou’i, Amir
A1 Kurd, Ramzi
A1 Ben-Chetrit, Eli
A1 Danziger, Guy
A1 Papan, Cihan
A1 Motov, Sergey
A1 Shapira, Ma’anit
A1 Stein, Michal
A1 Klein, Adi
A1 Gottlieb, Tanya M
A1 Eden, Eran
YR 2021
UL http://medrxiv.org/content/early/2021/07/02/2021.06.27.21259196.abstract
AB BACKGROUND Accurately identifying COVID-19 patients at-risk to deteriorate remains challenging. Tools integrating host-protein expression have proven useful in determining infection etiology and hold potential for prognosticating disease severity.METHODS Adults with COVID-19 were recruited at medical centers in Israel, Germany, and the United States. Severe outcome was defined as intensive care unit admission, non-invasive or invasive ventilation, or death. Tumor necrosis factor related apoptosis inducing ligand (TRAIL) and interferon gamma inducible protein-10 (IP-10; also known as CXCL10) and C-reactive protein (CRP) were measured using an analyzer providing values within 15 minutes. A signature indicating the likelihood of severe outcome was derived generating a score (0-100). Patients were assigned to 4 score bins.RESULTS Between March and November 2020, 518 COVID-19 patients were enrolled, of whom 394 were eligible, 29% meeting a severe outcome. The signature’s area under the receiver operating characteristic curve (AUC) was 0.86 (95% confidence interval: 0.81-0.91). Performance was not confounded by age, sex, or comorbidities and superior to IL-6 (AUC 0.77; p = 0.033) and CRP (AUC 0.78; p < 0.001). Likelihood of severe outcome increased significantly (p < 0.001) with higher scores. The signature differentiated patients who further deteriorated after meeting a severe outcome from those who improved (p = 0.004) and projected 14-day survival probabilities (p < 0.001).CONCLUSION The derived immune-protein signature combined with a rapid measurement platform is an accurate predictive tool for early detection of COVID-19 patients at-risk for severe outcome, facilitating timely care escalation and de-escalation and appropriate resource allocation.FUNDING MeMed funded the studyCompeting Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. AK, BT, GD, DD, MSt, MSa, PS declare they have: received no support from any organization for the submitted work; have no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. AA, EE, ER, ES, KO, MH, MR, NA, NSM, OS, RN, TIB, TMG, and YKI declare they are employees of MeMed, hold stock and/or options and receive salaries. PF declares he holds MeMed stock options. SL declares to have received lecturing fees from MeMed. EE, ES, KO, MH, NSM, OS, RN, SL, TIB, TMG declare they are authors of pending or issued patent applications relating to the submitted work. AJ, EBS, IK, KR, SM, IK declare that their medical center received funding from MeMed for the described clinical study. CP declares to have received a research grant from MeMed.Funding StatementMeMed funded the clinical study described in the manuscript. MeMed provided the measurement platforms and consumables.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Maimonides Medical Center, New York, US, IRB#: 2020-05-21 Saarland University Medical Center, Homburg, Germany, IRB#: 1009-20 Hillel Yaffe Medical Center, Hadera, Israel, IRB#: 0059-15 Shaare Zedek Medical Center, Jerusalem, Israel, IRB#: 0313-20 Beilinson Medical Center, Petah Tikva, Israel, IRB#: 0257-20 Hasharon Medical Center, Petah Tikva, Israel, IRB#: 0257-20All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.